Avalo Therapeutics, founded with a mission to address significant unmet clinical needs through precision medicine, is a clinical-stage biopharmaceutical company. The company focuses on discovering, developing, and commercializing targeted therapeutics for immune dysregulation. Avalo's product pipeline includes high-value, first-in-class biologics such as AVTX-, an anti-IL-1β monoclonal antibody for inflammatory diseases, quisovalimab (anti-LIGHT mAb), and AVTX- (BTLA agonist fusion protein).

Notable figures affiliated with Avalo Therapeutics include experienced leaders in biotechnology and pharmaceuticals. The company has garnered attention from prominent investors in the biopharma sector. Key achievements include the acquisition and development of their lead asset, AVTX-, which has shown promise in targeting inflammatory diseases. Avalo's precision medicine approach and innovative pipeline have positioned it as a significant player in the biopharmaceutical industry, aiming to improve patient outcomes through targeted therapies.